Salta al contenuto principale
Passa alla visualizzazione normale.

ANGELO BALDASSARE CEFALU'

Terapia biologica con infliximab (anti-TNF) nella malattia di Crohn: analisi delle complicanze.

  • Autori: Carroccio, A.; DI PRIMA, L.; Pirrone, G.; Ambrosiano, G.; Noto, D.; Cefalu', A.
  • Anno di pubblicazione: 2006
  • Tipologia: Articolo in rivista (Articolo in rivista)
  • OA Link: http://hdl.handle.net/10447/11963

Abstract

Anti-tumor necrosis factor (anti-TNF) therapy is an important therapeutic addition in the treatment of active Crohn's disease. Although controlled trials have confirmed the efficacy of anti-TNF (infliximab) treatment, serious toxicities related to the therapies have emerged. The purpose of this article was to review the safety profile of infliximab, and in particular analyse the infectious complications, the autoimmune disorders and the theoretical risk of cancer and lymphoma